The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | CLL trial updates from EHA 2022
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, talks on the changing landscape of chronic lymphocytic leukemia (CLL). Prof. Hillmen explains that the results of FLAIR (ISRCTN01844152) and GAIA/CLL13 (NCT02950051) trials have clearly demonstrated the superiority of targeted therapy over chemoimmunotherapy and have highlighted the efficacy of therapies combining targeted agents with monoclonal antibodies in patients with CLL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
